Latest Endo Pharmaceuticals Holdings Inc (ENDP) Headlines
Endo Pharmaceuticals Has Returned 29.8% Since SmarTrend Recommendation (ENDP)
Comtex SmarTrend(R) - Wed Mar 12, 11:02AM CDT
SmarTrend identified an Uptrend for Endo Pharmaceuticals (NASDAQ:ENDP) on November 5th, 2013 at $55.81. In approximately 4 months, Endo Pharmaceuticals has returned 29.83% as of today's recent price of $72.45.
Insider Trading Alert - ENDP, AAPL And DTE Traded By Insiders
at The Street - Wed Mar 12, 9:00AM CDT
Stocks with insider trader activity include ENDP, AAPL and DTE
Greenberg: What You May Have Missed
at The Street - Wed Mar 12, 8:33AM CDT
What you may have missed, including takes on Nu Skin, Clean Harbors and pharmaceutical mega mergers. It was a light week as I am working on new stories, but here is a roundup from last week's Reality Check. Plus, as an added bonus, there is a new red...
Update on Endo's Product Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 11:00AM CDT
The approval of Aveed has boosted Endo's top line.
This Week in Biotech: Put It in Print
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 08, 1:05PM CST
With the SPDR S&P Biotech Index up 62% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Higher Functioning Endogenous Opioid System Predicts Better Treatment Response For Neuropathic Pain Treated With Topical NSAIDs: Study
PR Newswire - Fri Mar 07, 1:00PM CST
Not only are neuropathic pain symptoms quite common in knee osteoarthritis (OA), but scientists can predict who will respond to treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) by assessing the nervous system's own capacity to regulate pain, new research suggests. Patients whose tests had indicated superior conditioned pain modulation (CPM) had less pain and fewer neuropathic symptoms at study's end, in results reported in a scientific poster today at the 30th Annual Meeting of the American Academy of Pain Medicine.
Endo Announces Appointment of Dr. Susan Hall as New Chief Scientific Officer and Global Head of R&D and Quality
PR Newswire Europe - Fri Mar 07, 6:31AM CST
Endo International plc announced today that it had appointed Susan Hall, Ph.D. as executive vice president, chief scientific officer and global head of research & development and quality, effective March 10, 2014. Dr. Hall will be based in Dublin, Ireland at Endo's new global corporate headquarters.
U.S. FDA Approves AVEED(TM) (Testosterone Undecanoate) Injectable Testosterone Replacement Therapy For Men Living With Hypogonadism, Or Low-T
PR Newswire - Thu Mar 06, 6:00AM CST
Endo International plc (NASDAQ: ENDP) (TSX: ENL) announced today that its operating company Endo Pharmaceuticals Inc. received U.S. Food and Drug Administration (FDA) approval of AVEED(TM) (testosterone undecanoate) injection for the treatment of adult men with hypogonadism (commonly known as Low-T) that is associated with a deficiency or absence of the male hormone testosterone. AVEED is a new prescription medicine indicated to produce serum testosterone levels in the normal range by administration of a single 3-mL (750 mg) intramuscular injection given once at initiation of therapy, at 4 weeks, and then every 10 weeks thereafter. It is expected to be available in early March.
This $23 Billion Long-Term Winner Has Been Buying Health Care and Lumber
Selena Maranjian, The Motley Fool - Motley Fool - Wed Mar 05, 4:17PM CST
The latest 13F season is commencing, when many money managers issue required reports on their holdings. It can be worthwhile to pay attention, as you might get an investment idea or two by seeing what some major investors have been buying and...
Endo Pharmaceuticals Has Returned 35.9% Since SmarTrend Recommendation (ENDP)
Comtex SmarTrend(R) - Wed Mar 05, 9:36AM CST
SmarTrend identified an Uptrend for Endo Pharmaceuticals (NASDAQ:ENDP) on November 5th, 2013 at $55.81. In approximately 4 months, Endo Pharmaceuticals has returned 35.90% as of today's recent price of $75.84.
American Realty Capital Properties and Cole Capital(TM) Name Michael Ezzell to Lead Private Capital Management Business
PR Newswire - Tue Mar 04, 5:00AM CST
American Realty Capital Properties, Inc. ("ARCP") and Cole Capital(TM), ARCP's private capital management business, jointly announced today the appointment of Michael Ezzell as Executive Vice President of Private Capital Markets.
Endo Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 3.76%
Comtex SmarTrend(R) - Mon Mar 03, 4:52PM CST
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $75.80 to a high of $79.03. Yesterday, the shares fell 3.8%, which took the trading range below the 3-day low of $75.86 on volume of 3.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Q4 Earnings Decline Y/Y at Endo, Weak Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 12:26PM CST
Earnings declined at Endo due to lower revenues.
A Busy Calendar of March Biotech Events
at The Street - Mon Mar 03, 12:13PM CST
Drug approvals, FDA advisory panels and clinical trial results all on tap over the next 30 days.
Endo International acquires Paladin Labs for USD2.7bn
M2 - Mon Mar 03, 5:21AM CST
Health care company Endo International (Endo Health Solutions) (Nasdaq:ENDP)(TSX:ENL) reported on Friday the completion of its acquisition of Paladin Labs, valued at USD2.7bn, in a stock and cash transaction.
Endo Completes Acquisition of Paladin Labs
PR Newswire Europe - Fri Feb 28, 10:15AM CST
Accretive transaction accelerates Endo's transformation into a leading specialty healthcare company -- Creates a compelling financial and operational platform for future growth -- Establishes Endo's global pharmaceuticals footprint -- Endo Health Solutions Inc. becomes Endo International plc Endo International plc , formerly Endo Health Solutions Inc., announced today that it has completed the acquisition of Paladin Labs Inc. in a stock and cash transaction currently valued at approximately $2.7 billion. The acquisition accelerates Endo's strategic transformation into a leading global specialty healthcare company and creates a platform for future growth in North America and around the globe.
Knight Therapeutics Inc. to Begin Trading on March 3, 2014
Marketwire - Fri Feb 28, 8:09AM CST
The Common Shares of Knight Therapeutics Inc. (TSX VENTURE: GUD) are now listed on the TSX Venture Exchange under the ticker symbol GUD and are expected to begin trading on March 3, 2014 at opening. Knight Therapeutics Inc. ("Knight") is owned by the former shareholders of Paladin Labs Inc. ("Paladin") pursuant to a spin-off transaction that was effected today, along with the acquisition of Paladin by Endo Health Solutions Inc. (NASDAQ: ENDP), a leading U.S.-based specialty pharmaceutical company.
Endo Pharmaceuticals Has Returned 29.8% Since SmarTrend Recommendation (ENDP)
Comtex SmarTrend(R) - Wed Mar 12, 11:02AM CDT
SmarTrend identified an Uptrend for Endo Pharmaceuticals (NASDAQ:ENDP) on November 5th, 2013 at $55.81. In approximately 4 months, Endo Pharmaceuticals has returned 29.83% as of today's recent price of $72.45.
Insider Trading Alert - ENDP, AAPL And DTE Traded By Insiders
at The Street - Wed Mar 12, 9:00AM CDT
Stocks with insider trader activity include ENDP, AAPL and DTE
Greenberg: What You May Have Missed
at The Street - Wed Mar 12, 8:33AM CDT
What you may have missed, including takes on Nu Skin, Clean Harbors and pharmaceutical mega mergers. It was a light week as I am working on new stories, but here is a roundup from last week's Reality Check. Plus, as an added bonus, there is a new red...
Update on Endo's Product Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 11:00AM CDT
The approval of Aveed has boosted Endo's top line.
This Week in Biotech: Put It in Print
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 08, 1:05PM CST
With the SPDR S&P Biotech Index up 62% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Higher Functioning Endogenous Opioid System Predicts Better Treatment Response For Neuropathic Pain Treated With Topical NSAIDs: Study
PR Newswire - Fri Mar 07, 1:00PM CST
Not only are neuropathic pain symptoms quite common in knee osteoarthritis (OA), but scientists can predict who will respond to treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) by assessing the nervous system's own capacity to regulate pain, new research suggests. Patients whose tests had indicated superior conditioned pain modulation (CPM) had less pain and fewer neuropathic symptoms at study's end, in results reported in a scientific poster today at the 30th Annual Meeting of the American Academy of Pain Medicine.
Endo Announces Appointment of Dr. Susan Hall as New Chief Scientific Officer and Global Head of R&D and Quality
PR Newswire Europe - Fri Mar 07, 6:31AM CST
Endo International plc announced today that it had appointed Susan Hall, Ph.D. as executive vice president, chief scientific officer and global head of research & development and quality, effective March 10, 2014. Dr. Hall will be based in Dublin, Ireland at Endo's new global corporate headquarters.
U.S. FDA Approves AVEED(TM) (Testosterone Undecanoate) Injectable Testosterone Replacement Therapy For Men Living With Hypogonadism, Or Low-T
PR Newswire - Thu Mar 06, 6:00AM CST
Endo International plc (NASDAQ: ENDP) (TSX: ENL) announced today that its operating company Endo Pharmaceuticals Inc. received U.S. Food and Drug Administration (FDA) approval of AVEED(TM) (testosterone undecanoate) injection for the treatment of adult men with hypogonadism (commonly known as Low-T) that is associated with a deficiency or absence of the male hormone testosterone. AVEED is a new prescription medicine indicated to produce serum testosterone levels in the normal range by administration of a single 3-mL (750 mg) intramuscular injection given once at initiation of therapy, at 4 weeks, and then every 10 weeks thereafter. It is expected to be available in early March.
This $23 Billion Long-Term Winner Has Been Buying Health Care and Lumber
Selena Maranjian, The Motley Fool - Motley Fool - Wed Mar 05, 4:17PM CST
The latest 13F season is commencing, when many money managers issue required reports on their holdings. It can be worthwhile to pay attention, as you might get an investment idea or two by seeing what some major investors have been buying and...
Endo Pharmaceuticals Has Returned 35.9% Since SmarTrend Recommendation (ENDP)
Comtex SmarTrend(R) - Wed Mar 05, 9:36AM CST
SmarTrend identified an Uptrend for Endo Pharmaceuticals (NASDAQ:ENDP) on November 5th, 2013 at $55.81. In approximately 4 months, Endo Pharmaceuticals has returned 35.90% as of today's recent price of $75.84.
American Realty Capital Properties and Cole Capital(TM) Name Michael Ezzell to Lead Private Capital Management Business
PR Newswire - Tue Mar 04, 5:00AM CST
American Realty Capital Properties, Inc. ("ARCP") and Cole Capital(TM), ARCP's private capital management business, jointly announced today the appointment of Michael Ezzell as Executive Vice President of Private Capital Markets.
Endo Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 3.76%
Comtex SmarTrend(R) - Mon Mar 03, 4:52PM CST
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $75.80 to a high of $79.03. Yesterday, the shares fell 3.8%, which took the trading range below the 3-day low of $75.86 on volume of 3.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Q4 Earnings Decline Y/Y at Endo, Weak Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 12:26PM CST
Earnings declined at Endo due to lower revenues.
A Busy Calendar of March Biotech Events
at The Street - Mon Mar 03, 12:13PM CST
Drug approvals, FDA advisory panels and clinical trial results all on tap over the next 30 days.
Endo International acquires Paladin Labs for USD2.7bn
M2 - Mon Mar 03, 5:21AM CST
Health care company Endo International (Endo Health Solutions) (Nasdaq:ENDP)(TSX:ENL) reported on Friday the completion of its acquisition of Paladin Labs, valued at USD2.7bn, in a stock and cash transaction.
Endo Completes Acquisition of Paladin Labs
PR Newswire Europe - Fri Feb 28, 10:15AM CST
Accretive transaction accelerates Endo's transformation into a leading specialty healthcare company -- Creates a compelling financial and operational platform for future growth -- Establishes Endo's global pharmaceuticals footprint -- Endo Health Solutions Inc. becomes Endo International plc Endo International plc , formerly Endo Health Solutions Inc., announced today that it has completed the acquisition of Paladin Labs Inc. in a stock and cash transaction currently valued at approximately $2.7 billion. The acquisition accelerates Endo's strategic transformation into a leading global specialty healthcare company and creates a platform for future growth in North America and around the globe.
Knight Therapeutics Inc. to Begin Trading on March 3, 2014
Marketwire - Fri Feb 28, 8:09AM CST
The Common Shares of Knight Therapeutics Inc. (TSX VENTURE: GUD) are now listed on the TSX Venture Exchange under the ticker symbol GUD and are expected to begin trading on March 3, 2014 at opening. Knight Therapeutics Inc. ("Knight") is owned by the former shareholders of Paladin Labs Inc. ("Paladin") pursuant to a spin-off transaction that was effected today, along with the acquisition of Paladin by Endo Health Solutions Inc. (NASDAQ: ENDP), a leading U.S.-based specialty pharmaceutical company.
